Skip to content
Biodatica
Start free

PrECOG, LLC.

Location not on file

OncologymRNAPhase III
Compare Sign in to watch

What changed

Phase III trial registered: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

2mo agoTrial registeredMay 18, 2026Source filing (opens the source filing in a new tab)

Momentum

65no change

Momentum 65 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE3 registered

    Jul 1, 2026

    Multiple Myeloma · NOT_YET_RECRUITING · sponsor: PrECOG, LLC. · Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

    ClinicalTrials.gov · NCT07285239 (opens the source filing in a new tab)

  2. Grant

    R01 · $649k · non-dilutive

    Sep 10, 2024

    UNIVERSITY OF CALIFORNIA BERKELEY · PI STAHL, ANDREAS · NIDDK · award ends Jun 30, 2028 · Role of Biomechanical Interfaces Created by Focal Adhesion Kinase in Catecholamine Signaling

    NIH RePORTER · NIH RePORTER 11189733 (opens the source filing in a new tab)

  3. Grant

    R16 · $188k · non-dilutive

    Aug 10, 2024

    ST. JOHN'S UNIVERSITY · PI KUMAR, SUNIL · NIGMS · award ends Jun 30, 2028 · Investigating the role of Lipocalin Prostaglandin D2 Synthase and its metabolite PGD2 in non-alcoholic fatty liver disease

    NIH RePORTER · NIH RePORTER 11166340 (opens the source filing in a new tab)

  4. Grant

    T32 · $188k · non-dilutive

    Jul 1, 2022

    UNIVERSITY OF CALIFORNIA BERKELEY · PI STAHL, ANDREAS · NIDDK · award ends Jun 30, 2027 · Training Program in Metabolic Biology

    NIH RePORTER · NIH RePORTER 11124637 (opens the source filing in a new tab)

  5. Grant

    R01 · $528k · non-dilutive

    May 1, 2012

    UNIVERSITY OF CALIFORNIA BERKELEY · PI SCHAFFER, DAVID V · NINDS · award ends Apr 30, 2027 · Mechanisms of Neural Stem Cell Mechanoregulation

    NIH RePORTER · NIH RePORTER 11081743 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources